Center for Breakthrough Medicines

Center for Breakthrough Medicines is an innovative contract development and manufacturing organization (CDMO) specializing in advanced cell and gene therapies. Founded in 2019, the company is dedicated to accelerating the speed to market for life-changing treatments. Their integrated, one-source service offering encompasses a comprehensive suite of solutions designed for the full product lifecycle. This includes high-quality process and analytical development, viral vector manufacturing, GMP testing, cell therapy bioprocessing, plasmid production, and cell banking services. Operating with a client-driven approach and a patient-centric culture, Center for Breakthrough Medicines aims to deliver reliable and efficient manufacturing capabilities for complex biological therapies. Meet Center for Breakthrough Medicines' team to learn more about their operational expertise and leadership in the field.

The company operates within the Pharmaceutical and Healthcare industries, positioning itself as a key player in the rapidly evolving cell and gene therapy sector. With a reported revenue of $36.6 million and an employee range of 500 - 1,000 individuals, Center for Breakthrough Medicines demonstrates significant operational scale. Its strategic location in Cellicon Valley further enhances its access to talent and resources. The organization is committed to providing end-to-end solutions, from discovery and pre-clinical stages through to commercial manufacturing, addressing critical challenges in bringing novel therapies to patients.

In January 2022, Center for Breakthrough Medicines secured substantial funding, raising $350 million in Private Equity from SK Inc., highlighting strong investor confidence in its growth trajectory and market potential. This financial backing supports its mission to advance the development and manufacturing of cutting-edge therapies. The company'sView more...